[TruScreen联合高危人乳头瘤病毒检测与Thinprep细胞学检测联合高危人乳头瘤病毒检测用于宫颈癌筛查的临床比较研究]。

Q3 Medicine

四川大学学报(医学版) Pub Date : 2025-05-20 DOI:10.12182/20250560609

Yi Yang, Chunmei Li, Shuyun Jia, Yifeng Wang, Dengpan Wang, Liyin Zhang

{"title":"[TruScreen联合高危人乳头瘤病毒检测与Thinprep细胞学检测联合高危人乳头瘤病毒检测用于宫颈癌筛查的临床比较研究]。","authors":"Yi Yang, Chunmei Li, Shuyun Jia, Yifeng Wang, Dengpan Wang, Liyin Zhang","doi":"10.12182/20250560609","DOIUrl":null,"url":null,"abstract":"Objective: To compare the clinical value of TruScreen, an artificial intelligence-based real-time cervical cancer screening system, combined with high-risk human papillomavirus (hr-HPV) test and Thinprep cytology test (TCT) combined with hr-HPV test in cervical cancer screening.Methods: A total of 297 women undergoing cervical cancer screening at Panzhihua Central Hospital between June 2020 and December 2023 were enrolled. All participants underwent hr-HPV testing, TCT, and TruScreen test. The diagnostic performance of TruScreen combined with hr-HPV test and TCT combined with hr-HPV test for low-grade squamous intraepithelial lesion positive (LSIL+) and high-grade squamous intraepithelial lesion positive (HSIL+) cervical lesions was evaluated.Results: Among the 297 enrolled women, pathology analysis identified 128 (43.10%) LSI+ cases and 67 (22.56%) HSIL+ cases. Additionally, there were 110 (37.04%) HPV16/18 positive cases, 177 (59.60%) cases with TCT results ≥ atypical squamous cells of undetermined significance (ASCUS), and 176 (59.26%) cases with abnormal TruScreen results. The area under the curve (AUC) of TruScreen combined with hr-HPV test in diagnosing LSIL+ and HSIL+ cervical lesions was higher than that of TCT combined with hr-HPV test (P < 0.05).Conclusion: TruScreen combined with hr-HPV test demonstrates superior performance in cervical cancer screening compared with TCT combined with hr-HPV test. TruScreen combined with hr-HPV test may serve as an alternative to conventional cytology-based methods for cervical cancer screening in China.","PeriodicalId":39321,"journal":{"name":"四川大学学报(医学版)","volume":"56 3","pages":"852-857"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439646/pdf/","citationCount":"0","resultStr":"{\"title\":\"[TruScreen Combined With High-Risk Human Papillomavirus Testing vs Thinprep Cytology Test Combined With High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: A Comparative Clinical Study].\",\"authors\":\"Yi Yang, Chunmei Li, Shuyun Jia, Yifeng Wang, Dengpan Wang, Liyin Zhang\",\"doi\":\"10.12182/20250560609\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To compare the clinical value of TruScreen, an artificial intelligence-based real-time cervical cancer screening system, combined with high-risk human papillomavirus (hr-HPV) test and Thinprep cytology test (TCT) combined with hr-HPV test in cervical cancer screening.Methods: A total of 297 women undergoing cervical cancer screening at Panzhihua Central Hospital between June 2020 and December 2023 were enrolled. All participants underwent hr-HPV testing, TCT, and TruScreen test. The diagnostic performance of TruScreen combined with hr-HPV test and TCT combined with hr-HPV test for low-grade squamous intraepithelial lesion positive (LSIL+) and high-grade squamous intraepithelial lesion positive (HSIL+) cervical lesions was evaluated.Results: Among the 297 enrolled women, pathology analysis identified 128 (43.10%) LSI+ cases and 67 (22.56%) HSIL+ cases. Additionally, there were 110 (37.04%) HPV16/18 positive cases, 177 (59.60%) cases with TCT results ≥ atypical squamous cells of undetermined significance (ASCUS), and 176 (59.26%) cases with abnormal TruScreen results. The area under the curve (AUC) of TruScreen combined with hr-HPV test in diagnosing LSIL+ and HSIL+ cervical lesions was higher than that of TCT combined with hr-HPV test (P < 0.05).Conclusion: TruScreen combined with hr-HPV test demonstrates superior performance in cervical cancer screening compared with TCT combined with hr-HPV test. TruScreen combined with hr-HPV test may serve as an alternative to conventional cytology-based methods for cervical cancer screening in China.\",\"PeriodicalId\":39321,\"journal\":{\"name\":\"四川大学学报(医学版)\",\"volume\":\"56 3\",\"pages\":\"852-857\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439646/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"四川大学学报(医学版)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12182/20250560609\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"四川大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12182/20250560609","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的：比较基于人工智能的宫颈癌实时筛查系统TruScreen联合高危人乳头瘤病毒（hr-HPV）检测和Thinprep细胞学检测（TCT）联合hr-HPV检测在宫颈癌筛查中的临床价值。方法：纳入2020年6月至2023年12月期间在攀枝花市中心医院接受宫颈癌筛查的297名妇女。所有的参与者都进行了hr-HPV检测、TCT和trusscreen检测。评价TruScreen联合hr-HPV检测和TCT联合hr-HPV检测对宫颈低级别鳞状上皮内病变阳性（LSIL+）和高级别鳞状上皮内病变阳性（HSIL+）的诊断效果。结果：在297名入组女性中，病理分析发现128例（43.10%）LSI+病例和67例（22.56%）HSIL+病例。HPV16/18阳性110例（37.04%），TCT结果≥非典型鳞状细胞不确定意义（ASCUS） 177例（59.60%），trusscreen结果异常176例（59.26%）。trusscreen联合hr-HPV检测诊断LSIL+、HSIL+宫颈病变的曲线下面积（AUC）高于TCT联合hr-HPV检测（P < 0.05）。结论：与TCT联合hr-HPV检测相比，TruScreen联合hr-HPV检测在宫颈癌筛查中的效果更佳。在中国，TruScreen联合hr-HPV检测可作为传统细胞学筛查方法的替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

[TruScreen Combined With High-Risk Human Papillomavirus Testing vs Thinprep Cytology Test Combined With High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: A Comparative Clinical Study].

查看原文本刊更多论文

Objective: To compare the clinical value of TruScreen, an artificial intelligence-based real-time cervical cancer screening system, combined with high-risk human papillomavirus (hr-HPV) test and Thinprep cytology test (TCT) combined with hr-HPV test in cervical cancer screening.

Methods: A total of 297 women undergoing cervical cancer screening at Panzhihua Central Hospital between June 2020 and December 2023 were enrolled. All participants underwent hr-HPV testing, TCT, and TruScreen test. The diagnostic performance of TruScreen combined with hr-HPV test and TCT combined with hr-HPV test for low-grade squamous intraepithelial lesion positive (LSIL⁺) and high-grade squamous intraepithelial lesion positive (HSIL⁺) cervical lesions was evaluated.

Results: Among the 297 enrolled women, pathology analysis identified 128 (43.10%) LSI⁺ cases and 67 (22.56%) HSIL⁺ cases. Additionally, there were 110 (37.04%) HPV16/18 positive cases, 177 (59.60%) cases with TCT results ≥ atypical squamous cells of undetermined significance (ASCUS), and 176 (59.26%) cases with abnormal TruScreen results. The area under the curve (AUC) of TruScreen combined with hr-HPV test in diagnosing LSIL⁺ and HSIL⁺ cervical lesions was higher than that of TCT combined with hr-HPV test (P < 0.05).

Conclusion: TruScreen combined with hr-HPV test demonstrates superior performance in cervical cancer screening compared with TCT combined with hr-HPV test. TruScreen combined with hr-HPV test may serve as an alternative to conventional cytology-based methods for cervical cancer screening in China.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

四川大学学报(医学版) Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

0.70

自引率

0.00%

发文量

8695

期刊介绍： "Journal of Sichuan University (Medical Edition)" is a comprehensive medical academic journal sponsored by Sichuan University, a higher education institution directly under the Ministry of Education of the People's Republic of China. It was founded in 1959 and was originally named "Journal of Sichuan Medical College". In 1986, it was renamed "Journal of West China University of Medical Sciences". In 2003, it was renamed "Journal of Sichuan University (Medical Edition)" (bimonthly). "Journal of Sichuan University (Medical Edition)" is a Chinese core journal and a Chinese authoritative academic journal (RCCSE). It is included in the retrieval systems such as China Science and Technology Papers and Citation Database (CSTPCD), China Science Citation Database (CSCD) (core version), Peking University Library's "Overview of Chinese Core Journals", the U.S. "Index Medica" (IM/Medline), the U.S. "PubMed Central" (PMC), the U.S. "Biological Abstracts" (BA), the U.S. "Chemical Abstracts" (CA), the U.S. EBSCO, the Netherlands "Abstracts and Citation Database" (Scopus), the Japan Science and Technology Agency Database (JST), the Russian "Abstract Magazine", the Chinese Biomedical Literature CD-ROM Database (CBMdisc), the Chinese Biomedical Periodical Literature Database (CMCC), the China Academic Journal Network Full-text Database (CNKI), the Chinese Academic Journal (CD-ROM Edition), and the Wanfang Data-Digital Journal Group.